Berlin Heals has developed the C‑MIC Device — a revolutionary, novel, and life‑changing treatment for people with heart failure. This minimally invasive, easy‑to‑implant microcurrent device has shown meaningful clinical benefits, including improved quality of life, greater exercise capacity, better heart‑failure status, and measurable structural improvements in the heart — results never seen before in heart‑failure patients.
The C-MIC Device
A Revolutionary Treatment for Heart Failure
The C‑MIC Device is a breakthrough cardiac implant that activates the heart’s own healing signals to restore function in patients with symptomatic, treatment‑resistant heart failure. This small, minimally invasive device delivers a steady, ultra‑low direct current (DC) that drives reverse remodeling of damaged heart muscle — enabling recovery that was previously out of reach.
More about our Solution
Impressive Clinical Results
Patients not only maintained their initial gains — they continued improving over six months of therapy, with long‑term follow‑up showing benefits that remained stable for up to 30 months.
Berlin Heals is now conducting a European-wide Landmark Double-Blind Sham-Controlled Trial and advancing toward a Global Pivotal Study, Patients not only maintained their initial gains — they continued improving through six months of therapy, with long‑term follow‑up showing durable benefits lasting up to 30 months.
Heart Failure Explained
Heart Failure is the World’s Most Lethal Disease
Heart failure is a progressive condition that develops when the heart can no longer pump enough blood and oxygen to meet the body’s needs. For decades, available therapies have focused on managing symptoms and slowing decline — leaving patients with limited options.
Berlin Heals was founded in 2014 to challenge this reality with a truly innovative and groundbreaking approach to heart‑failure care.
Studies
Study Plan
A first‑in‑human study was completed in 2019 with follow‑up extending to 30 months. An international, multi‑center randomized controlled trial followed from 2022–2024, with results published in 2025; these patients are also being monitored for 30‑month outcomes.
A less‑invasive first‑in‑human study was completed in 2025, with results presented as a Late‑Breaking Clinical Trial in May 2026. Berlin Heals is now enrolling a European‑wide, double‑blind, sham‑controlled trial that includes a broader range of ejection fractions and both non‑ischemic and ischemic heart‑failure populations.
